Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
NCT05479240Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in rectal adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05479240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479240.